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Abstract
Recent blue-ribbon panel reports have concluded that HIV treatment programs in less wealthy countries must integrate
mental health identification and treatment into normal HIV clinical care and that research on mental health and HIV in these
settings should be a high priority. We assessed the epidemiology of depression in HIV patients on antiretroviral therapy in a
small urban setting in Cameroon by administering a structured interview for depression to 400 patients consecutively
attending the Bamenda Regional Hospital AIDS Treatment Center. One in five participants met lifetime criteria for MDD, and
7% had MDD within the prior year. Only 33% had ever spoken with a health professional about depression, and 12%
reported ever having received depression treatment that was helpful or effective. Over 2/3 with past-year MDD had severe
or very severe episodes. The number of prior depressive episodes and the number of HIV symptoms were the strongest
predictors of past-year MDD. The prevalence of MDD in Cameroon is as high as that of other HIV-associated conditions, such
as tuberculosis and Hepatitis B virus, whose care is incorporated into World Health Organization guidelines. The
management of depression needs to be incorporated in HIV-care guidelines in Cameroon and other similar settings.
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Introduction
More than 25 million people have died from HIV/AIDS, most
of them in sub-Saharan Africa (SSA) where HIV/AIDS is the
leading cause of mortality. [1] In 2010, SSA accounted for
approximately two-thirds of global cases. [1] Despite recent global
initiatives to improve the availability of and access to antiretroviral
therapy (ART) in SSA, the continued high adult mortality due to
HIV/AIDS in this region results in significant social and economic
consequences.
Cameroon, located in central Africa, has an estimated 550,000
persons living with HIV and an HIV prevalence rate of 5.5%. [2]
In a number of ways, Cameroon’s experience with HIV is
representative of many SSA countries. The HIV prevalence in
Cameroon approximates the mean HIV prevalence in SSA
(6.8%). [2] Further, as with the majority of low- and middle-
income countries, and the majority of SSA nations, 20–39%
percent of those eligible for ART receives the medications. [1]
Cameroon is also one of 22 priority countries identified in the
World Health Organization’s ‘‘Global Plan’’ as a key target
because of the high estimated numbers of pregnant women living
with HIV. [3]
Mental disorders, especially depression, are common in HIV-
infected persons globally. The HIV/AIDS Costs and Services
Utilization Study (HCSUS) study, a U.S. national study of HIV-
infected individuals, found that nearly half (48%) of participants
had a probable mental disorder. [4] The major mood and anxiety
disorders are five to ten times more prevalent in HIV-positive
individuals than in the general U.S. population, [5] with a similar
increased risk found in SSA settings. [6] The most common
psychiatric diagnoses among HIV-positive individuals are mood
and anxiety disorders, particularly MDD and other depressive
disorders. [5,6,7,8,9,10] Similar data are limited for persons with
HIV in SSA generally and, to the best of our knowledge, are
lacking for Cameroon.
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Depression is associated with worse HIV-related outcomes. In
individuals with HIV/AIDS, mental illness (MI) in general and
depression in particular, have been consistently associated with
negative HIV-related behaviors, particularly poor ART adher-
ence, a critical consideration in HIV care where ART plays a
central role in suppressing virus and protecting the immune
system. [11,12,13,14,15,16,17] A recent meta-analysis of 95
studies encompassing 35,029 participants confirmed the consistent
association of depression with poor ART adherence low-resource
and high-resource settings. [18] Additionally, depression predicts a
higher likelihood of engaging in unsafe needle-sharing and sexual
behaviors that risk secondary transmission of HIV infection.
[19,20] Depression has also been associated with poorer physical
health, [21] decreased quality of life, [22] and AIDS-related
mortality. [23] Thus, identifying those at risk of a depressive illness
can highlight patients especially in need of active follow-up.
Recent prominent blue-ribbon panel reports have concluded
that HIV treatment programs in less wealthy countries must
integrate mental health identification and treatment into normal
HIV clinical care and that research on mental health and HIV
should be a high priority, especially in less wealthy countries. [24]
Cameroon is one such country, and no prior studies of depression
prevalence in HIV patients in Cameroon exist.
Accordingly, we sought:
N To determine the prevalence of clinically relevant depressive
illness in HIV patients in a small urban setting in Cameroon,
and
N To describe the severity of MDD in the patient population and
to identify sociodemographic and clinical variables associated
with a greater risk of depressive illness.
Methods
Ethical Approvals
This research was approved by the Institutional Review Boards
of the University of North Carolina, Duke University, and the
Cameroon National Ethics Committee.
Study Design/Population
Bamenda, a city in northwestern Cameroon and capital of the
North West Province, has a population of 269,530, [25] making it
the country’s third most populated center. We conducted a cross-
sectional study of HIV-infected patients on antiretroviral therapy
(ART) attending the Bamenda Regional Hospital AIDS Treat-
ment Center (BRHATC). This health facility is dedicated to the
care of HIV-infected patients, the vast majority of whom are on
ART. The center provides care to over 1,000 patients annually.
Between May 2010 and October 2010, attendees of the BRHATC
were informed of the study through thrice-weekly health education
sessions. Patients were eligible if they were HIV-infected, on ART,
were attending the BRHATC for any service (including counsel-
ing, clinical follow-up or drug refill), spoke English, and were
willing to provide informed consent. Although more than 30 local
languages exist, English is the language used for regular clinical
care in the BRHATC and throughout the Northwest Region of
Cameroon; more than 95% of clinic attendees can communicate
effectively in English. Each participant could be eligible only once
during the study period.
Our sampling goal was to recruit a study sample representative
of HIV-infected patients receiving antiretroviral therapy at
BRHATC. In the absence of a daily patient register to provide
a sampling frame, study staff approached each patient consecu-
tively as the patients passed through a central point in the
registration process (weight measurement) until a patient indicated
willingness to participate in the study. The recruiting staff member
then obtained written informed consent from the interested patient
and completed the first part of data collection. The patient would
then complete the second part of data collection with a second staff
member while the recruiting staff member resumed approaching
patients consecutively at registration.
Instruments
Lifetime and recent Major Depressive Disorder (MDD) were
assessed using the World Health Organization’s Composite
International Diagnostic Instrument (CIDI), a lay-administered
diagnostic instrument whose performance has been validated
widely in multiple international settings, [26,27] including HIV
settings. [6] The CIDI is a comprehensive, fully structured
interview designed to be used by trained lay interviewers for the
assessment of mental disorders in epidemiological and cross-
cultural studies as well as for clinical and research purposes. We
used the World Mental Health Survey Initiative Version of the
CIDI (WMH-CIDI), which allows the assessment of mental
disorders according to the definitions and criteria of ICD-10 and
DSM-IV. [28,29] The diagnostic section of the interview expands
upon earlier versions of the CIDI by adding detailed questions
about disorder severity, impairment, service use, and treatment,
and has improved generalizability with increased involvement of
less wealthy countries. [29,30] This version has been successfully
used in Sub-Saharan Africa (Nigeria). [29,30] We administered
the Screening and Depression modules of the WMH-CIDI.
Interviews were conducted in person by a health care professional
who received formal CIDI training from a WHO-certified trainer.
Measures
Following standard CIDI scoring methodology, participants
were assigned a diagnosis of a lifetime episode of MDD if they
described ever experiencing a period meeting the following
criteria: a period lasting at least two weeks characterized by at
least 5 out of 9 core depressive symptoms, with at least one
symptom being either depressed mood or anhedonia, and
representing a change from previous functioning; the symptoms
caused clinically significant distress or impairment in social,
occupational, or other important areas of functioning; the
symptoms were not better explained by substance use or a general
medical condition; and the symptoms were not better explained by
bereavement, or if secondary to bereavement, the episode either
lasted more than two months or was characterized by at least one
of the following: marked functional impairment, morbid preoccu-
pation with worthlessness, suicidal ideation, psychotic symptoms,
or psychomotor retardation.
On the CIDI, participants reporting any lifetime episode of
MDD were asked if they had experienced any similar episodes in
the past year, past 6 months, and past month. Participants
reporting an episode in the past year or more recently completed a
standard depressive severity rating scale called the Quick
Inventory of Depressive Symptoms (QIDS) [31] that is embedded
within the CIDI. The QIDS total score can range from 0–27 and
has standard categories that correspond to very severe (21–27),
severe (16–20), moderate (11–15), mild (6–10), and no (0–5)
depressive symptoms. Participants were classified as having a
diagnosis of a MDD in the past year, past 6 months, and past
month if they endorsed a depressive episode in those time frames
and received a score of 11 or above on the QIDS.
Participants additionally provided information on socio-demo-
graphics and on whether in the past 6 months they had
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experienced each of 13 symptoms commonly associated with HIV
infection: [4] new or persistent headaches, fevers, oral pain, white
patches in the mouth, rashes, nausea, trouble with eyes, sinus
infection, numbness in the hands or feet, persistent cough,
diarrhea, weight loss, or (for women only) abnormal vaginal
discharge.
Statistical Analysis
Participant characteristics, prevalence of depression, and
characteristics of depressive episodes are described with propor-
tions or medians and interquartile ranges (IQR). We describe
continuous variables with medians and interquartile ranges due to
the skewed distributions of some of these variables. Logistic
regression was used to examine potential predictors of a diagnosis
of depression in the past 6 months and in the past year. Odds
ratios (OR) from bivariable analyses are used to describe the
association of each predictor variable with depression. Age
(divided by 10) and number of reported HIV symptoms were
each modeled as simple linear terms after confirmation of the
appropriateness of this assumption. Thus the OR for age
represents the predicted increase in the odds of depression
associated with a 10-year increase in age, and the OR for HIV
symptoms represents the predicted increase in the odds of
depression associated with each additional HIV symptom report-
ed. For multivariable logistic regression analyses, the number of
variables to be included in each of the models was decided a priori
based on prevalence of the outcome; variables were selected for
inclusion based on prior knowledge of relationship to the outcome
and on relevance to the study question. All statistical analyses were
carried out using Stata statistical software (version 11.1; STATA
Corp, College Station, Texas).
Results
General Characteristics of Study Population
Of the 400 HIV-infected participants enrolled in the study,
nearly L were female and most were between 34 and 47 years of
age (median 41 years) (Table 1). Most had previously been married
(44%) or were currently married or cohabitating (34%). The
majority (61%) had no more than a primary level of education (#6
years). Participants reported a median of 5 (IQR: 3–6) physical
symptoms commonly associated with HIV infection.
Prevalence of MDD and Clinical Features
One in five participants met lifetime criteria for major
depressive disorder (Table 2). The prevalence of MDD was 7%
in the prior year, 5% in the prior 6 months, and 3% in the prior
month.
For those who had experienced MDD in their lifetime, the
median age at first onset of MDD was 34 years, and the median
number of lifetime episodes was 2. The median length of the 1st
episode was 122 days (approximately 4 months). Only 1/3 had
ever spoken with a physician or other health professional about
depression, and 1/8 (12%) reported ever having received
treatment that was helpful or effective for their depression.
Characterizing the Most Recent Depressive Episode
Among those with MDD in the past year, the severity of the
current episode (among those currently experiencing a major
depressive episode) or the worst episode in the past year was
pronounced, as reflected by a mean score of 16 on the QIDS
instrument. As measured by the QIDS, 2/3 of patients depressed
within the past year had either a severe (59%) or very severe (7%)
episode (Figure 1).
Table 1. Characteristics of the overall study population (N [%]
or median [IQR]).











Previously married 178 44
Never married 85 21
Education*
Primary 245 61
Greater than primary 155 39







HIV symptom score (possible range: 0–13) 5 3–6
*Primary = 6 years or fewer; greater than primary = more than 6 years.
**In US dollars, approximation based on reported weekly expenditures in FCFC.
***By interviewer assessment.
doi:10.1371/journal.pone.0041699.t001
Table 2. Prevalence of depression diagnoses (N, % or
median, IQR).
Study population, n = 400
N/median %/IQR
Depression Diagnosis
Past Month 11 3
Past 6 Months 20 5
Past Year 29 7
Lifetime 84 21
Number of lifetime episodes 2 1–3
Lifetime Diagnosis, n = 84
Age at 1st onset, years 34 25–40
Length of 1st episode, days 122 30–1095
Ever talk to MD/other professional 28 33
Ever receive effective depression treatment 10 12
Past-year Diagnosis, n = 29
QIDS score 16 14–18
doi:10.1371/journal.pone.0041699.t002
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We further delineated the specific depressive symptoms
endorsed by depressed HIV-infected patients on the QIDS, as
indicated by endorsing a symptom as present (Table 3). Among
those with an episode in the past year, depressed mood and
anhedonia were extremely common and nearly always presented
together (97% of the sample reported each alone, and 100%
had at least one of the two.) All depressed patients endorsed
some type of insomnia (most commonly middle insomnia) and
decreased attention/concentration. Nearly all endorsed feeling
worthless or guilty and having a decreased level of energy (97%
for each). Psychomotor retardation, weight change (nearly
always weight loss), and appetite change (nearly always
decreased appetite) were similarly frequently reported (93%,
93%, and 90% respectively). Restlessness and too much sleep
were less frequently reported (73% and 59%, respectively).
Thoughts of death or suicide were frequently endorsed by
depressed HIV patients (86%).
For those patients who endorsed suicidal ideation, most
reported having passive thoughts without active thoughts of
harming themselves (Table 4). The great majority of those
endorsing suicidal ideation reported thoughts that life was not
worth living but had no thoughts of suicide, consistent with passive
suicidal ideation (80%); 16% reported thoughts of suicide or death
several times per week; and 4% endorsed plans or having recently
made an attempt.
Correlates of Depression Diagnosis–bivariable Analysis
With bivariable analysis, we assessed whether common predic-
tors were correlated with depressive diagnoses within the past year
in this sample (Table 5). Females tended to be less likely than
males to have depression, although this finding was not statistically
significant. Older patients tended to be less likely to have MDD
than younger ones. Those with education beyond the primary
level tended to be twice as likely to have MDD as those with only
primary education.
Two variables stood out as significant predictors of MDD within
the past year. First, the number of HIV symptoms was positively
associated with the odds of having MDD within the past year.
Each additional HIV symptom was associated with approximately
a 20% increased odds of MDD. Second, prior history of MDD was
the strongest risk factor for MDD within the past year. For those
with a history of one episode of MDD more than a year ago, the
likelihood of MDD within the past year increased nearly seven-
fold compared to those without such a history, while a prior
history of two or more episodes of MDD increased the likelihood
of MDD within the past year by more than twelve-fold.
Correlates of Depression Diagnosis–multivariable
Analysis
Considering all these variables together in a multivariable
analysis, findings remained consistent, with the number of prior
depressive episodes and the number of HIV symptoms having
significant associations with past-year MDD similar in magnitude
Figure 1. Categorized distribution of scores on the Quick Inventory of Depressive Symptomatology (QIDS) tool among participants
with past-year depression.
doi:10.1371/journal.pone.0041699.g001
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to those found in bivariable analyses (Table 6). Female patients
and patients living in rural areas tended to be less likely to have
MDD within the preceding year.
Discussion
In this sample of HIV-infected patients receiving antiretroviral
therapy and attending a regional AIDS treatment center in
Cameroon, 3% met criteria for a major depressive episode within
the past month, 5% had an episode within the past 6 months, 7%
had an episode in the past year, and 21% met criteria for major
depressive disorder at some point in their life. These prevalence
values are consistent with prior reports on the frequency of MDD
in African HIV-infected populations receiving antiretroviral
therapy as determined by structured diagnostic interviews in
which functional impairment is part of the diagnosis, such as the
CIDI. Maj et al. reported that past month prevalence of MDD in
Nairobi, Kenya was 3.0% and 5.5% in asymptomatic and
symptomatic HIV-infected patients, respectively; rates in Kin-
shasa, Democratic Republic of the Congo, were 0 and 4.4%,
respectively. [6] Current MDD was present in 2.7% of HIV-
infected patients in a rural setting in Muheza, Tanzania. [32]
A small number of more recent studies have used as the
diagnostic standard either the PRIME-MD mood module [33] or
Mini International Neuropsychiatric Interview, [34,35,36,37,38]
tools which do not consider functional impairment in diagnosing
MDD. Accordingly, these studies may employ a more sensitive but
less specific instrument to detect depression. These studies have
reported a greater range of prevalence and higher rates of MDD,
ranging from 8–34% in samples of HIV-infected individuals from
Botswana, Nigeria, South Africa, and Uganda.
[33,34,35,36,37,38] In any case, our findings, coupled with those
already reported in the literature, identify depression as an illness
in Cameroon with a prevalence as high as that of other HIV-
associated conditions, such as tuberculosis (0.041%) [39] and
Hepatitis B virus (8.3%), [40] which have care recommendations
incorporated into World Health Organization guidelines. [41]
Further, the lifetime MDD prevalence of 21% in this sample
was 2–3 times higher than what has been reported in urban sub-
Table 3. Depressive symptoms endorsed.
Current episode/worst episode in last year (n = 29)
N %
Feeling sad 28 97
Anhedonia 28 97
Any insomnia 29 100
Initial insomnia 26 90
Middle insomnia 29 100
Terminal insomnia 24 83
Decreased attention/concentration 29 100
Feeling worthless/guilty 28 97
Decreased level of energy 28 97
Psychomotor retardation 27 93
Weight changes 27 93
Weight gain 2 7
Weight loss 25 86
Appetite changes 27 90
Decreased appetite 26 90
Increased appetite 0 0
Thoughts of death/suicide 25 86
Restlessness 21 72
Too much sleep 17 59
doi:10.1371/journal.pone.0041699.t003
Table 4. Description of Suicidal Ideation.
Depression Diagnosis in Past Year with Suicidal
Ideation (n = 25)
N %
Life empty/not worth living 20 80
Thoughts of suicide/death several times/week 4 16
Thoughts of suicide/death several times/day w/plans or attempt 1 4
doi:10.1371/journal.pone.0041699.t004
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Saharan African settings, suggesting that the burden of depression
in HIV patients may be greater than expected based on studies in
major African cities. Indeed, in Nairobi, Kenya, 6.1% of
asymptomatic patients and 9.7% of symptomatic patients had a
lifetime history of MDD, and in Kinshasa (Democratic Republic of
Congo), 3.8% and 7.3%, respectively, had a lifetime history of
MDD. [6]
Identification and successful management of MDD by a health
care professional, a key objective of blue-ribbon panel reports and
the World Health Organization, [24] was uncommon. Discussion
of depression with clinicians was low, with only 1/3 reporting
having spoken with a health professional about the depression, and
only 1/8 reported every receiving helpful or effective depression
treatment.
Key variables discriminating between HIV-infected patients
with and without depression were the number of prior lifetime
episodes and the number of physical symptoms potentially related
to HIV. In adjusted analyses, having one prior episode of MDD
increased the risk of having a recent MDD episode by over five-
fold, while having two or more prior episodes increased the risk of
recent MDD by over eleven-fold. We found no other reports on
how prior history of MDD in HIV patients affected the risk of a
recent MDD. For clinicians, then, a key clinical piece of
information in evaluating current depression is whether a patient
has a history of depressive episodes.
Similarly, having a greater number of HIV symptoms increased
the odds of having MDD within the past year. This finding is
consistent with reports of prior studies suggesting an association
between depression and severity of HIV illness. [42,43]
Depressive symptomatology in this population mirrored pre-
sentations of depression in other settings, and was notable for
infrequent reports of weight gain or increased appetite. Middle
insomnia, experienced by all depressed HIV patients in this
sample, is a symptom that HIV clinicians might be able to address
quickly and effectively with amitriptyline, the most commonly used
and widely available antidepressant in Cameroon.
Suicidal ideation was common in depressed HIV patients
(86%), but it was primarily passive, described as thoughts that life
was not worth living rather than having active thoughts of self-
harm. This high frequency of suicidal ideation in general with a
low frequency of specifically active suicidal ideation is consistent
with prior studies of depression in medical settings. [44]
Finally, the majority of individuals with MDD experienced
severe rather than moderate depressive symptoms and were
substantially impaired. Indeed, 2/3 met criteria for being severely
or very severely depressed, which is a greater proportion than was
reported in a rural sample in Tanzania (2/3 moderately depressed,
1/3 severely depressed). [32]
Our findings are limited by a number of issues. First, while
consistent with prior reports, our prevalence of current depression
was still smaller than we expected, limiting our ability to
comprehensively assess variables predictive of major depressive
disorder. We used a well validated and culturally translated
instrument, and depression diagnoses were carefully reviewed by a
psychiatrist, so the measurement of depression is likely to have
high construct validity. The large majority of cases of depression
were severe or very severe, so the predictors identified are likely to
be good predictors of severe, clinically relevant depressive
disorders with substantial impairment. Second, following our
Table 5. Correlates of depression diagnosis – bivariable
analysis.





Female 0.63 0.28, 1.41
Age* 0.82 0.50, 1.23
Marital Status
Married/cohabitating REF
Previously married 1.12 0.46, 2.70
Never married 1.27 0.45, 3.54
Education
Primary REF
Greater than primary 2.04 0.95, 4.36
Number of prior lifetime depressive episodes
0 REF
1 6.63 2.13, 20.59
2+ 12.14 4.51, 32.67
HIV Symptoms** 1.19 1.05, 1.36
Village of residence
Urban REF
Rural 0.81 0.37, 1.80
*Estimates for a 10-year increase in age.
**For each additional symptom.
doi:10.1371/journal.pone.0041699.t005
Table 6. Correlates of depression diagnosis – multivariable
analysis.




Female 0.61 0.23, 1.64
Age* 1.03 0.61, 1.73
Marital Status
Married/cohabitating REF
Previously married 1.57 0.53, 4.62
Never married 1.24 0.36, 4.32
Education
Primary REF
Greater than primary 1.03 0.38, 2.81
Number of prior lifetime depressive episodes
0 REF
1 5.42 1.65, 17.75
2+ 11.38 4.04, 32.04
HIV Symptoms** 1.22 1.05, 1.42
Village of residence
Urban REF
Rural 0.72 0.29, 1.81
*Estimates for a 10-year increase in age.
**For each additional symptom.
doi:10.1371/journal.pone.0041699.t006
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diagnostic reference standard, the CIDI, we collected a full report
on depressive symptoms only on patients with MDD, so we could
not identify depressive symptoms that distinguish between
clinically depressed HIV patients and HIV patients with mild
depressive symptoms who are not clinically depressed. Such
information would be helpful to HIV clinicians to focus on key
depressive symptoms that might differentiate those at higher risk of
clinical depression. Third, these data are from a single site in a
small urban center in Cameroon, which may limit their
generalizability. However, findings here were generally consistent
with what has been reported in other sub-Saharan Africa sites.
Fourth, in the assessment of predictors of MDD, there may be
some uncontrolled confounding because of the small number of
variables that could be included in the multivariate analysis.
Finally, most of the variables and measurements were self-
reported, so their accuracy is dependent on the veracity of the
participants.
Conclusions
This study of HIV-positive outpatients attending a hospital in a
small urban center in Bamenda, Cameroon, found that 7% had
depression at some point within the past year, most of which was
severe or very severe. Identification and successful management of
MDD by a health care professional was infrequent. Suicidal
ideation was common, although usually passive. Important
predictors of a major depressive episode in the past year were
prior history of depression and a greater number of HIV
symptoms. Future research can look at interventions to help
HIV clinicians better identify and manage this common and
complicating comorbidity. The management of depression
(including screening and appropriate care) needs to be incorpo-
rated in HIV-care guidelines in Cameroon and other similar
settings, as its prevalence is as high as those of other HIV-
associated conditions such as tuberculosis and hepatitis B infection
whose management is included in such guidelines.
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